Radar · Life Sciences in Redwood City
Best Life Sciences Companies in Redwood City, United States
The 107 best Life Sciences companies in Redwood City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Auris Health.
By Riya SenguptaFinancials
107companies tracked
$8.5Bdisclosed funding
0unicorns
69have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × REDWOOD CITY
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
883kcombined LinkedIn audience
66%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Redwood City
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Auris Health Robotic surgical system for medical intervention | $733M | 90 mo ago | 242 | 2007 | Christopher Velis Co-Founder | 1,865 patents Robotic-assisted minimally invasive surgical instruments and navigation systems for endoscopic procedures. | — |
| 2 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | 2012 | Shankar Ramaswamy Co-Founder & CEO | — | — |
| 3 | Guardant Health Developer of digital sequencing technology for cancer detection 90Patents top 14%Funding top 15%Innovation top 17%Moat top 19% All 13 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Moattop 19% Markettop 23% Techtop 23% Newstop 29% Growthtop 30% Producttop 35% Fin. healthtop 36% Partnerstop 41% Globaltop 45% Talenttop 46% Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $557M | 7 mo ago | 1,351 | 2012 | Amirali Talasaz Co-founder and Co-Chief Executive Officer | 996 patents Liquid biopsy cfDNA sequencing and analysis for cancer detection and monitoring | 1 launch · 1 partnership |
| 4 | Synthego Developer of CRISPR-engineered cell and gene therapies | $460M | 52 mo ago | 328 | 2012 | — | 123 patents Automated synthesis and stabilization of CRISPR guide RNAs and nucleic acid reagents | — |
| 5 | Maze Therapeutics Developer of genetic bio-markers in neurological, metabolic, and renal diseases 53Funding top 22%News top 24%Growth top 31%Moat top 46% All 9 signals ▾Fundingtop 22% Newstop 24% Growthtop 31% Moattop 46% Marketbottom 49% Techbottom 49% Fin. healthbottom 44% Talentbottom 40% Globalbottom 39% Funding: Raised $381M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 9 BI events in 12 mo (of 23 tracked, 5 types) · +125% YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $381M | 9 mo ago | 111 111 → 155 (+40%) · sector median +30% | 2018 | Jason Coloma CEO | — | — |
| 6 | PROCEPT BioRobotics Developer of a therapeutic device for benign prostatic hyperplasia | $349M | 33 mo ago | 217 | 2009 | — | 269 patents Robotic minimally invasive surgical probes for tissue resection, monitoring, and optical treatment | — |
| 7 | Exo Developer of point of care ultrasound ecosystem with AI-powered diagnostic and workflow tools 72Funding top 15%Talent top 28%AI top 30%Tech top 31% All 10 signals ▾Fundingtop 15% Talenttop 28% AItop 30% Techtop 31% Moattop 31% Growthtop 45% Markettop 46% Innovationbottom 43% Patentsbottom 42% Globalbottom 39% Funding: Raised $346M across 10 rounds · 10 rounds over 7 yrs (1.4/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $346M | 12 mo ago | 152 152 → 185 (+22%) · sector median +30% | 2015 | Sandeep Akkaraju CEO/Founder | 10 patents Patents concentrated in electrical & electronics | — |
| 8 | Karius Provider of diagnostics for identifying infectious diseases using microbial DNA | $315M | 25 mo ago | 139 139 → 212 (+53%) · sector median +30% | 2014 | Tim Blauwkamp Chief Scientific Officer | 81 patents Rapid metagenomic sequencing workflows for pathogen detection and microbial biomarker analysis. | — |
| 9 | MapLight Developer of therapeutic for central nervous system disorders 50Funding top 13%Growth top 28%Talent top 38%Moat top 39% All 7 signals ▾Fundingtop 13% Growthtop 28% Talenttop 38% Moattop 39% Globalbottom 39% Marketbottom 33% Techbottom 32% Funding: Raised $305M across 7 rounds · 7 rounds over 6 yrs (1.2/yr) Growth: Headcount 20 → 27 (+35%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $305M | 11 mo ago | 27 | 2018 | Chris Kroeger Founder & CEO | — | — |
| 10 | Gynesonics Developer of minimally invasive treatment for uterine fibroids | $283M | 31 mo ago | 92 | 2005 | — | 228 patents Image-guided needle-based ablation systems for uterine fibroid treatment | — |
| 11 | Pulmonx Developer of smart devices for treating pulmonary diseases | $281M | 73 mo ago | 198 198 → 276 (+39%) · sector median +30% | 1998 | — | 313 patents Bronchoscopic devices and methods for lung diagnostics, imaging analysis, and volume reduction therapies | — |
| 12 | Relievant Medsystems Developer of medical devices for patients suffering from chronic vertebrogenic low back pain | $273M | 39 mo ago | 9 | 2004 | — | 252 patents Steerable spinal vertebral treatment devices and bone‑access nerve modulation technologies. | — |
| 13 | Relypsa Developer of drugs for treating cardiovascular and renal diseases | $208M | 121 mo ago | 284 | 2007 | — | 270 patents Patents concentrated in health & consumer products | — |
| 14 | Pliant Developer of drugs related to Fibrosis, COVID-19, and Muscular Dystrophies | $207M | 75 mo ago | 158 | 2016 | — | 183 patents Advanced barrier and vented packaging films for food, medical and perishable goods | — |
| 15 | Revolution Medicines Developer of therapies for the treatment of cancer | $181M | 79 mo ago | 181 | 2014 | Kevan Shokat Co-Founder | 807 patents Small-molecule inhibitors of Ras signaling and mTOR pathways for targeted cancer therapy | 1 award |
| 16 | Bolt Biotherapeutics Developer of T-cell therapies for the treatment of cancer | $177M | 60 mo ago | 94 94 → 47 (-50%) · sector median +30% | 2015 | Edgar Engleman Founder | 256 patents Targeted immunotherapy using antibody‑drug conjugates and innate immune agonists. | — |
| 17 | Avinger Provider of image-guided catheter-based products for peripheral artery disease | $171M | 27 mo ago | 80 | 2007 | — | 302 patents Intravascular atherectomy and imaging catheters for treating and navigating vascular occlusions | — |
| 18 | Minerva Surgical Innovating minimally invasive solutions for women's uterine health and well-being | $170M | 40 mo ago | 155 155 → 93 (-40%) · sector median +30% | 2008 | David Clapper CEO | 217 patents Uterine tissue resection and extraction devices for minimally invasive endometrial procedures | — |
| 19 | Armo BioSciences Immune modulatory biologic therapeutics for cancer, Atherosclerosis, fibrosis and inflammatory bowel disease | $167M | 96 mo ago | 21 | 2012 | — | 158 patents Therapeutic IL-10 biologics for immunomodulation and cancer immunotherapy | — |
| 20 | Dermiria Topical products to treat psoriasis, hyperhidrosis, and acne. | $162M | 89 mo ago | 4 | 2011 | Thomas Wiggans CEO | — | — |
| 21 | Natera Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 74 mo ago | 3,293 3,293 → 5,831 (+77%) · sector median +30% | 2004 | — | 625 patents Non‑invasive cfDNA sequencing for prenatal and cancer diagnostics and monitoring | 3 partnerships |
| 22 | Myoscience Non-opioid pain relief treatment using advanced cold technology | $148M | 91 mo ago | 687 | 2005 | — | 167 patents Patents concentrated in health & consumer products | — |
| 23 | Versartis Biopharma company developing long-acting therapeutic proteins for the treatment of endocrine disorders | $144M | 148 mo ago | 5 | 2008 | Jay Shepard CEO | — | — |
| 24 | Ashvattha Therapeutics Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases 45Funding top 23%Moat top 36%Talent top 38%Market bottom 41% All 6 signals ▾Fundingtop 23% Moattop 36% Talenttop 38% Marketbottom 41% Globalbottom 37% Newsbottom 22% Funding: Raised $130M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $130M | 17 mo ago | 40 | 2015 | Kannan Rangaramanujam Co-Founder & CTO | — | — |
| 25 | OncoMed Biopharmaceutical company focused on developing therapies for rare diseases | $117M | 150 mo ago | 22 | 2004 | — | — | — |
| 26 | Inquis Medical Developer of medical device for the treatment of peripheral thrombectomy | $115M | 5 mo ago | — | 2019 | Mojgan Saadat Co-Founder | — | 1 launch |
| 27 | Codexis Developer of high-performance enzymes for drug discovery | $111M | 84 mo ago | 276 276 → 240 (-13%) · sector median +30% | 2002 | Stephen Dilly CEO | 2,543 patents Engineered biocatalytic enzymes for industrial synthesis of fine chemicals and pharmaceuticals | — |
| 28 | Ambys Medicines Developer of cell therapies to treat severe liver diseases | $107M | 54 mo ago | 61 | 2018 | — | 18 patents Engineered hepatocyte production and biliary delivery systems for liver disease therapies | — |
| 29 | Arstasis Self-sealing artery access device | $102M | 151 mo ago | 28 | 2004 | — | 90 patents Minimally invasive vascular access and closure devices for interventional cardiology | — |
| 30 | Heron Therapeutics Pharmaceutical company focused on acute care and oncology with innovative therapies | $86M | 34 mo ago | 21 | 1983 | — | 202 patents Advanced drug delivery devices and pharmaceutical formulation technologies for injectable therapies | 2 job openings |
| 31 | Eyconis Developer of ophthalmology therapeutics for diseases like AMD, DME, RVO, and GA | $85M | 8 mo ago | — | 2024 | Emmett Cunningham Co-Founder & Executive Chairman of the Board | — | 1 job opening |
| 32 | ApniCure Home use device for the treatment of sleep apnea | $71M | 123 mo ago | 22 | 2007 | — | 79 patents Patents concentrated in health & consumer products | — |
| 33 | Verinata Non-invasive prenatal diagnostics | $58M | 169 mo ago | 2 | 2002 | Jeffrey Bird CEO | — | — |
| 34 | Biomea Developer of small molecules based precision medicine for treating genetically defined forms of cancer | $56M | 65 mo ago | 165 | 2017 | Thomas Butler Co-Founder & CEO | — | — |
| 35 | Jasper Therapeutics Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | $49M | 77 mo ago | — | 1999 | Judith Shizuru Co-Founder | — | — |
| 36 | LTZ Therapeutics Developer of immunotherapies to treat cancer and other diseases 35Funding top 26%Moat top 39%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 39% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $47M | 1 mo ago | 23 | 2021 | Martin Treder Co-Founder | — | — |
| 37 | Nuvig Therapeutics Developer of therapeutics to treat inflammatory and autoimmune diseases | $47M | 18 mo ago | 10 | 2022 | Greg Coffey Co-Founder | — | — |
| 38 | Barosense Restrictive oral and gastric implants to induce Satiety | $46M | 198 mo ago | 11 | 2001 | — | 117 patents Patents concentrated in health & consumer products | — |
| 39 | Capnia Diagnostic and therapeutic products for chronic diseases | $39M | 117 mo ago | 25 | 1999 | Michael Wong Co-Founder | 202 patents Exhaled breath gas analysis and respiratory monitoring devices for medical diagnostics | — |
| 40 | Meissa Vaccines Film and TV production company specializing in documentaries and investigative journalism | $33M | 80 mo ago | 18 | 2014 | — | 15 patents Chimeric RSV‑coronavirus vaccine proteins for immunogenic composition and delivery | — |
| 41 | Lumend Catheter based technology for crossing chronic occlusions in coronary and peripheral vascular disease | $30M | 250 mo ago | — | 1996 | Matt Selmon Co-Founder | 28 patents Advanced catheter systems for crossing and re-entering vascular occlusions and embolization. | — |
| 42 | Teon Therapeutics Developer of small molecules of drugs for cancer immunotherapy | $30M | 63 mo ago | 9 | 2018 | Jim Liu Co-Founder | — | — |
| 43 | C2 Therapeutics Speciality company thear develops ablation therapies for GI tract infections | $29M | 114 mo ago | 16 | 2007 | — | 1,872 patents Patents concentrated in chemistry & materials | — |
| 44 | Voyage Medical Personalized primary care services focused on patient-centered care and overall well-being | $24M | 166 mo ago | — | 2006 | Vahid Saadat CEO | — | — |
| 45 | Cervel Non-invasive neuromodulation through transcranial magnetic stimulation to treat treatment resistant depression | $24M | 138 mo ago | 11 | 2008 | — | — | — |
| 46 | Betteromics Online platform for the analysis of omics clinical data | $20M | 31 mo ago | 45 | 2019 | — | 2 patents Integrated multi‑omics tumor profiling for precision oncology diagnostics | — |
| 47 | Nēsos Provider of wearable interface device for the brain regain control of immune function | $16M | 66 mo ago | 9 | 2017 | — | 58 patents Dual‑speed trailer jacks with clutch mechanisms for heavy‑duty trailer lifting. | — |
| 48 | IntraVu Manufacturer of image diagnostic device for doctors | $15M | 57 mo ago | 18 | 2014 | Stephanos Papademetriou Founder & CEO | 11 patents Miniaturized endoscopic imaging and visualization tools for minimally invasive airway and hand surgeries | — |
| 49 | EIGEN THERAPEUTICS Developer of combination therapeutics for cancer treatment | $7M | 27 mo ago | 6 | 2021 | Transon Nguyen CEO & Co-Founder | — | — |
| 50 | Endiatx Developer of robotic capsules for treating and diagnosing GI disorders | $4M | 32 mo ago | 9 | 2018 | Torrey Smith Co-Founder & CEO | 35 patents Swallowable robotic capsules for active GI navigation, imaging, and targeted therapy | — |
Top 12 Life Sciences companies in Redwood City
#1
Public · Redwood City, California · founded 2012 · 1351 employees$557.5Mraised▾
Public · Redwood City, California · founded 2012 · 1351 employees
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Fliar Intelligence Index™ 90how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Moat
top 19%Market
top 23%Tech
top 23%Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 · Latest publication 2026
Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (Nov 2025)
Innovation: 996 patents (top 3% of patent-holders) · 615 filings since 2022 vs 346 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 275k LinkedIn followers — 31.2% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Cancer Research UK Science and Innovation and The Royal Marsden NHS Foundation Trust) announced in 12 mo
Funding rounds
- Nov 2025Post IPO$350M
- Nov 2020Post IPO$1B
- Aug 2017Series E$360M
- Jan 2016Series D$100M
Founders & team
Investors
Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8, Heritage Group
Tech stack
Amazon Web ServicesAosApache Http ServerApple Icloud MailBootstrapBugherd
#2
Series B · Redwood City, California · founded 2021 · 23 employees$47Mraised▾
Series B · Redwood City, California · founded 2021 · 23 employees
Developer of immunotherapies to treat cancer and other diseases. The company focuses on the development of immunotherapies that are capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science technology.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Moat
top 39%Talent
bottom 49%Market
bottom 40%Global
bottom 36%Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Finance Coordinator (R&D), Medical/Sr. Med Director (MD) – Early Clinical Development
Activity (LinkedIn): 1 partnerships (incl. GlisoSmithKline (GSK)) announced in 12 mo
Funding rounds
- May 2026Series B$38M
- Jul 2024Series A$20M
- May 2023Seed$10M
- Apr 2022Seed$17M
Founders & team
Investors
Qiming Venture Partners, Shunwei Capital, K2 Venture Capital, Tigermed, Lapam Capital, K2VC
#3
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#4
Public · Redwood City, California · founded 2018 · 111 employees$381Mraised▾
Public · Redwood City, California · founded 2018 · 111 employees
Maze Therapeutics is involved in developing genetic biomarkers. The company is developing technologies in an integrated manner to identify genetic modifiers. It mainly focuses on genetic modifiers in neurological, metabolic and renal diseases, as well as oncology.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 22%News
top 24%Growth
top 31%Moat
top 46%Market
bottom 49%Tech
bottom 49%Funding: Raised $381M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Post IPO (Sep 2025)
News: 9 BI events in 12 mo (of 23 tracked, 5 types) · +125% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Headcount 77 → 111 (+44%) across vintages · Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 28k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Sep 2025Post IPO$150M
- Dec 2024Series D$115M
- Jan 2022Series C$190M
- Oct 2019Series C—
Founders & team
Investors
Third Rock Ventures, Arch Venture Partners, Google Ventures, Foresite Capital, Casdin Capital, Alexandria Venture Investments
Tech stack
Amazon Web ServicesApple Icloud MailDocusignGoogle AnalyticsHttp/3Jquery
#5
Series C · Redwood City, California · founded 2019$115Mraised▾
Series C · Redwood City, California · founded 2019
Developer of medical device for the treatment of peripheral thrombectomy. It offers AVENTUS Precision Thrombectomy System that is designed to treat venous thromboembolic diseases such as pulmonary embolism and deep vein thrombosis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Jan 2026Series C$75M
- Nov 2024Series B$40M
Founders & team
Investors
Marshall Wace, ShangBay Capital, Yu Galaxy, EnPointe Ventures
#6
Public · Redwood City, California · founded 2018 · 27 employees$305Mraised▾
Public · Redwood City, California · founded 2018 · 27 employees
Developer of therapeutic for central nervous system disorders. The company's flagship product ML-004 helps in treating mental disorders, Alzheimer's agitation, and others. It has also developed ML-007, ML-009 for treating dyskinesia, schizophrenia, and ML-016 for treating anhedonia.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 13%Growth
top 28%Talent
top 38%Moat
top 39%Global
bottom 39%Market
bottom 33%Funding: Raised $305M across 7 rounds · 7 rounds over 6 yrs (1.2/yr) · Last round Series D (Jul 2025)
Growth: Headcount 20 → 27 (+35%) across vintages · Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 17k LinkedIn followers
Funding rounds
- Jul 2025Series D$372.5M
- Oct 2023Series C$225M
- Jul 2023Series C$50M
- Mar 2021Series B$30M
Founders & team
Investors
Novo Holdings, 5AM Ventures, Cowen, The Michael J. Fox Foundation, Forbion, Goldman Sachs
Tech stack
Animate.CssComplianzCore-JsDocusignElementorGenesis Blocks
#7
Series C · Redwood City, California · founded 2015 · 152 employees$346Mraised▾
Series C · Redwood City, California · founded 2015 · 152 employees
Developer of point of care ultrasound ecosystem with AI-powered diagnostic and workflow tools. It provides handheld ultrasound devices that replaces carts and probes designed for medical imaging at the point of care. It offers technology that automates image capture and quantification. The ecosystem includes workflow software designed around the user.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 15%Talent
top 28%AI
top 30%Tech
top 31%Moat
top 31%Growth
top 45%Funding: Raised $346M across 10 rounds · 10 rounds over 7 yrs (1.4/yr) · Last round Series C (May 2025)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
AI: Classified as an AI company · Product described with: ai-powered
Audience (LinkedIn): 21k LinkedIn followers — 2.4% of this cohort's audience
Funding rounds
- May 2025Series C$43.9M
- Jan 2025Conventional Debt$8.8M
- Jul 2024Conventional Debt$20.7M
- Jul 2021Series C$220M
Founders & team
Investors
TDK Ventures, Solasta Ventures, Applied Materials, Action Potential Venture Capital, Intel Capital, Bold Capital Partners
Tech stack
Amazon SesAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementContentful
#8
Series C · Redwood City, California · founded 2024$85.3Mraised▾
Series C · Redwood City, California · founded 2024
Developer of ophthalmology therapeutics for diseases like AMD, DME, RVO, and GA. It focuses on creating long-acting and effective delivery methods for clinically validated and emerging medicines used in treating major causes of blindness. With TransCon technology for ophthalmology, it aims to develop transformational therapies for eye diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Hiring: 5 hiring posts in 12 mo (public) · momentum -3 · hiring: Senior Research Associate / Associate Scientist, Associate Scientist / Scientist
Funding rounds
- Oct 2025Series C$25M
- Jan 2024Series C$60.3M
Founders & team
Tech stack
Apple Icloud MailCloudflareGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#9
Series B · Redwood City, California · founded 2015 · 40 employees$130.4Mraised▾
Series B · Redwood City, California · founded 2015 · 40 employees
Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases. The company uses hydroxyl dendrimer technology to selectively target inflamed tissue, and its pipeline highlights migaldendranib (MGB) as a key candidate for ophthalmology, neurology, and inflammatory diseases.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 23%Moat
top 36%Talent
top 38%Market
bottom 41%Global
bottom 37%News
bottom 22%Funding: Raised $130M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) · Last round Series B (Jan 2025)
Moat: Editorial + unicorn rating 7/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Jan 2025Series B$50M
- Apr 2022Series B$69M
- Apr 2021Series A$60.2M
- May 2019Seed$250K
Founders & team
Investors
Huadong Medicine, Plum Alley Investments, Tribe Capital, Natural Capital Investment Fund, Natural Capital, Helios Capital
#10
Series B · Redwood City, California · founded 2022 · 10 employees$47Mraised▾
Series B · Redwood City, California · founded 2022 · 10 employees
Developer of therapeutics to treat inflammatory and autoimmune diseases. The company is advancing transformational therapies to restore immune homeostasis, and rebalance immune function. The company is developing a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Office Manager / Administrative Assistant
Activity: 1 awards announced in 12 mo
Funding rounds
- Dec 2024Series B$161M
- May 2022Series A$47M
Founders & team
Investors
Novo Holdings, Plantus, Bristol-Myers Squibb, Digitalis Ventures, Mission BioCapital, Sanofi Ventures
#11
Series C · Redwood City, California · founded 2014 · 139 employees$315Mraised▾
Series C · Redwood City, California · founded 2014 · 139 employees
Provider of diagnostics for identifying infectious diseases using microbial DNA. It offers Karius Test that uses clinical metagenomics specifically microbial cell-free DNA, or mcfDNA plus AI and sequencing to detect pathogens such as bacteria, fungi, viruses, parasites in the body from non-invasive samples.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 13k LinkedIn followers
Funding rounds
- May 2024Series C$100M
- Feb 2020Series B$165M
- Nov 2018Conventional Debt$25M
- Aug 2017Series A$50M
Founders & team
Investors
General Catalyst, HBM Healthcare Investments, Khosla Ventures, Lightspeed Venture Partners, SoftBank Vision Fund, S28 Capital
Tech stack
Amazon Web ServicesApple Icloud MailAppnexusCart FunctionalityCloudflareCloudflare Bot Management
#12
Public · Redwood City, California · founded 2007 · 80 employees$170.8Mraised▾
Public · Redwood City, California · founded 2007 · 80 employees
Avinger is a commercial-stage medical device company that develops, manufactures and sells image-guided, catheter-based products for treating peripheral artery disease. Its suite of products includes the Lightbox imaging console, as well as the Wildcat, Kittycat and Ocelot range of catheters.
Funding rounds
- Mar 2024Post IPO$15M
- Mar 2022Post IPO—
- Sep 2014Series E$34.8M
- Nov 2013Series D$10.5M
Investors
Zylox-Tonbridge, PDL Biopharma, CRG, Emergent Medical Partners, Black Diamond Ventures, Lucas Venture Group
Tech stack
BootstrapCloudflareCloudflare Bot ManagementContact Form 7Core-JsDraftpress Hfcm
Funding & investor landscape
$8.5Btotal disclosed funding
72companies funded
320disclosed rounds
1rounds last 90 days
Most active investors
New Enterprise Associates5 rounds
Notable founders
Amirali Talasaz
Co-founder and Co-Chief Executive Officer · Guardant Health
Roberto Mignone
Board of Directors · Guardant Health
Martin Treder
Co-Founder · LTZ Therapeutics
Shankar Ramaswamy
Co-Founder & CEO · Kriya Therapeutics
Roger Jeffs
Co-Founder · Kriya Therapeutics
Jason Coloma
CEO · Maze Therapeutics
Mojgan Saadat
Co-Founder · Inquis Medical
Vahid Saadat
Co-Founder & CEO · Inquis Medical
Chris Kroeger
Founder & CEO · MapLight
Christopher Kroeger
Founder & CEO · MapLight
Sandeep Akkaraju
CEO/Founder · Exo
John Kokulis
Co-Founder · Exo
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
How many Life Sciences companies are there in Redwood City, United States?
Radar tracks 107 indexable Life Sciences companies headquartered in Redwood City, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Redwood City, United States?
The Life Sciences companies in Redwood City, United States on this list have raised a combined $8.5B in disclosed equity funding across 72 funded companies.
Which is the highest-funded Life Sciences company in Redwood City, United States?
Auris Health is the highest-funded Life Sciences company in Redwood City, United States, with $733.2M in disclosed equity funding.
How many Life Sciences companies in Redwood City, United States are funded?
72 of the 107 Life Sciences companies in Redwood City, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Redwood City, United States?
None of the Life Sciences companies in Redwood City, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Redwood City, United States Life Sciences companies?
The most active investors in Redwood City, United States Life Sciences companies on this list include De Novo Ventures, RA Capital Management, Vivo Capital, Foresite Capital, Kleiner Perkins.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.